Background: Choice of minimum legal age (MLA) for cannabis use is a critical and contentious issue in legalization of non-medical cannabis. In Canada where non-medical cannabis was recently legalized in October 2018, the federal government recommended age 18, the medical community argued for 21 or even 25, while public consultations led most Canadian provinces to adopt age 19. However, no research has compared later life outcomes of first using cannabis at these different ages to assess their merits as MLAs.
Methods: We used doubly robust regression techniques and data from nationally representative Canadian surveys to compare educational attainment, cigarette smoking, self-reported general and mental health associated with different ages of first cannabis use.
Results: We found different MLAs for different outcomes: 21 for educational attainment, 19 for cigarette smoking and mental health and 18 for general health. Assuming equal weight for these individual outcomes, the 'overall' MLA for cannabis use was estimated to be 19 years. Our results were robust to various robustness checks.
Conclusion: Our study indicated that there is merit in setting 19 years as MLA for non-medical cannabis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222435 | PMC |
http://dx.doi.org/10.1186/s12889-020-08639-z | DOI Listing |
Anal Bioanal Chem
January 2025
Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, USA.
An increasing number of cannabis-related products have become available and entered the market, particularly those containing cannabidiol (CBD) and Δ-tetrahydrocannabinol (Δ-THC). Analytical methods for cannabinoids in urine have been described extensively in the literature. However, methods providing good resolution for distinguishing interferences from THC positional isomers are needed.
View Article and Find Full Text PDFJ Public Health Policy
January 2025
Research Centre, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada.
Several jurisdictions have implemented legalization policies for non-medical cannabis, mainly towards improving public health and reducing illegal cannabis markets and crime. As some legalization initiatives are approaching maturity, conducting policy impact assessments has become timely. Emerging data, however, suggest rather mixed pictures for key outcomes and indicators.
View Article and Find Full Text PDFSubst Abuse Treat Prev Policy
January 2025
Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Objective: Given the changes in trends of cannabis use (e.g., product types), this study examined latent classes of young adult use and associations with use-related outcomes.
View Article and Find Full Text PDFCannabis
December 2024
Peter Boris Centre for Addictions Research, St. Joseph's Healthcare Hamilton.
Objective: Little is known about the population-level impact of recreational cannabis legalization on trends in opioid-related mortality. Increased access to cannabis due to legalization has been hypothesized to reduce opioid-related deaths because of the potential opioid-sparing effects of cannabis. The objective of this study was to examine the relations between national retail sales of recreational (non-medical) cannabis and opioid overdose deaths in the 5 years following legalization in Canada.
View Article and Find Full Text PDFCNS Drugs
January 2025
Cognitive and Clinical Neuroimaging Core, McLean Hospital, McLean Imaging Center, Belmont, MA, USA.
The relationship between cannabis use and mental health is complex, as studies often report seemingly contradictory findings regarding whether cannabis use results in more positive or negative treatment outcomes. With an increasing number of individuals using cannabis for both recreational (i.e.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!